The transcription factor nuclear factor-kB (NF-kB) regulates genes important for tumor invasion, metastasis and chemoresistance. Normally, NF-kB remains sequestered in an inactive state by cytoplasmic inhibitor-of-kB (IkB) proteins. NF-kB translocates to nucleus and activates gene expression upon exposure of cells to growth factors and cytokines. We and others have shown previously that NF-kB is constitutively active in a subset of breast cancers. In this study, we show that constitutive activation of NF-kB leads to overexpression of the antiapoptotic genes c-inhibitor of apoptosis 2 (c-IAP2) and manganese superoxide dismutase (Mn-SOD) in breast cancer cells. Furthermore, expression of the antiapoptotic tumor necrosis factor receptor associated factor 1 (TRAF1) and defender-against cell death (DAD-1) is regulated by NF-kB in certain breast cancer cells. We also demonstrate that NF-kB-inducible genes protect cancer cells against paclitaxel as MDA-MB-231 breast cancer cells modi®ed to overexpress IkBa required lower concentrations of paclitaxel to arrest at the G2/M phase of the cell cycle and undergo apoptosis when compared to parental cells. The eect of NF-kB on paclitaxel-sensitivity appears to be speci®c to cancer cells because normal ®broblasts derived from embryos lacking p65 subunit of NF-kB and wild type littermate embryos were insensitive to paclitaxel-induced G2/M cell cycle arrest. Parthenolide, an active ingredient of herbal remedies such as feverfew (tanacetum parthenium), mimicked the eects of IkBa by inhibiting NF-kB DNA binding activity and Mn-SOD expression, and increasing paclitaxel-induced apoptosis of breast cancer cells. These results suggest that active ingredients of herbs with anti-in¯ammatory properties may be useful in increasing the sensitivity of cancers with constitutively active NF-kB to chemotherapeutic drugs. Oncogene (2000) 19, 4159 ± 4169.
Introduction
Fatality in breast cancer is generally due to metastasis and development of resistance to chemotherapy (Fisher, 1994; Liotta et al., 1991) . Metastasis and resistance to chemotherapy are mostly due to overexpression of pro-metastatic, pro-angiogenic, multi-drug resistance and anti-apoptotic genes (Baldini, 1997; Fisher, 1994; Wang et al., 1999a) . The expression of a signi®cant number of these genes is regulated by NF-kB, Activator Protein-1 (AP-1) and the Ets family of transcription factors (Baeuerle and Henkel, 1994; Grumont et al., 1999; Gutman and Wasylyk, 1990; Lee et al., 1999; Wang et al., 1998 Wang et al., , 1999b Zong et al., 1999) . Drugs that inhibit the activity of these transcription factors, therefore, may be useful in overcoming metastasis and chemoresistance.
Expression of the pro-metastatic genes interleukin-6 (IL-6), urokinase plasminogen activator, matrix metalloproteinase 9, the pro-angiogenic gene IL-8 and the anti-apoptotic genes c-IAP1, c-IAP2, TRAF1, TRAF2, B¯-1/A1, Bcl-X L and Mn-SOD is induced by NF-kB (Baeuerle and Henkel, 1994; Grumont et al., 1999; Jones et al., 1997; Lee et al., 1999; Wang et al., 1998 Wang et al., , 1999b Zong et al., 1999) . Normally, NF-kB resides in the cytoplasm in an inactive state bound to IkB proteins (Baeuerle and Henkel, 1994) . When cells are exposed to TNFa, IL-1 or chemotherapeutic agents, a multisubunit IkB kinase complex (IKC) is activated, which phosphorylates IkBs (Zandi and Karin, 1999) . NF-kB dissociates from phosphorylated IkBs, translocates to the nucleus and activates target genes (Baeuerle and Henkel, 1994) . The ability of activated NF-kB to induce gene expression depends on the cell type and the type of NF-kB inducer. For example, in cell types that are sensitive to TNFa and chemotherapy-induced apoptosis, NF-kB is inactivated by caspases and the induction of NF-kBdependent cell survival signals is markedly reduced (Levkau et al., 1999) . In contrast, activation of NFkB by growth factors or IL-1 can cause an increase in anti-apoptotic gene expression and subsequent resistance to TNF and chemotherapy (Wang et al., 1996) . Inhibition of NF-kB activation by IkB overexpression can convert TNF-and chemotherapy-resistant cells to a sensitive phenotype (Beg and Baltimore, 1996; Van Antwerp et al., 1996; Wang et al., 1996) . These results suggests that gene therapy with IkBs or drugs with anti-NF-kB properties are useful in overcoming chemoresistance of cancers that contain constitutively active NF-kB.
A number of drugs with anti-NF-kB properties have been described. The anti-in¯ammatory drug aspirin and salicylate inhibit the activity of IKKb of IKC and prevent NF-kB activation (Yin et al., 1998) . Sequiterpene lactones derived from Mexican Indian medicinal plants inhibit NF-kB activity through distinct mechanisms (Bork et al., 1997) . For example, while helenalin inhibit NF-kB DNA binding activity by alkylating p65 subunit of NF-kB, parthenolide inhibits the activity of IKC (Hehner et al., 1999; Lyss et al., 1998) . Unlike aspirin and salicylate, parthenolide appears to be a highly speci®c inhibitor of NF-kB (Hehner et al., 1999) . Moreover, parthenolide is the active ingredient of the herb feverfew, which is frequently used as a migraine prophylaxis (Murphy et al., 1988) . Therefore, parthenolide is a potential NF-kB inhibitor that may overcome chemoresistance.
Recent studies indicate that NF-kB is constitutively active in a number of hematological and solid tumors including Hodgkin's lymphoma, melanoma, juvenile myelomonocytic leukemia, cutaneous T cell lymphoma, squamous cell carcinoma and Bcr-Abl-induced transformation (Bargou et al., 1997; Dong et al., 1999; Giri and Aggarwal, 1998; Reuther et al., 1998; Shattuck-Brandt and Richmond, 1997) . We, as well as others, previously demonstrated constitutive NFkB activation in a subset of breast cancers (Cogswell et al., 2000; Nakshatri et al., 1997; Sovak et al., 1997) . In this study, we have determined the antiapoptotic genes that are overexpressed in breast cancer cells with constitutively active NF-kB. We have also investigated the eects of constitutively active NF-kB on paclitaxel-induced G2/M arrest and apoptosis. Finally, we show that parthenolide decreases NF-kB DNA binding activity and increases the sensitivity of breast cancer cells to paclitaxel. These results suggest that parthenolide or herbs with similar anti-in¯ammatory substances may be useful complementary therapies in cancers with constitutively active NF-kB.
Results

Constitutive NF-kB activation in breast cancer cells correlates with increased c-IAP2 and Mn-SOD expression
Previously, we had demonstrated that constitutive NFkB DNA binding activity varies among breast cancer cell lines (Nakshatri et al., 1997; Newton et al., 1999) . The binding activity observed was MDA-MB-436 5 HBL100 4 MDA-MB-231 5 MDA-MB-468 5 MDA-MB-435 4 SK-BR-3 5 Hs578T 5 ZR-75-1 4 T47-D 5 MCF-7 cells (Newton et al., 1999) (Table  1) . Among these cells, MCF-7, T47-D and ZR-75-1 cells are estrogen receptor alpha (ERa)-positive (Sommers et al., 1994) . We and others have also demonstrated that in ERa-positive breast cancer cells, transcriptional activity but not DNA binding activity of NF-kB is inhibited by ERa (Galien and Garcia, 1997; Nakshatri et al., 1997) . We postulated that ERanegative breast cancer cells with higher levels of constitutive NF-kB DNA binding activity overexpress NF-kB-inducible genes compared to ERa-positive breast cancer cells. To address this possibility, we employed RNase protection assays, Northern analysis, cDNA microarray and dierential display methods to identify NF-kB regulated genes in breast cancer cells. The RNase protection assay was performed with hAPO-5 probe, which allows quantitation of xIAP, TRAF1, TRAF2, CART, NIAP, c-IAP1, c-IAP2, TRPM2 and CRAF genes. Among these genes, xIAP, TRAF1, TRAF2, c-IAP1, c-IAP2 and NIAP are antiapoptotic (Deveraux and Reed, 1999; Wang et al., 1998) . TRPM-2 is anti-apoptotic in certain cell types (Miyake et al., 2000) . There was no signi®cant variation in the expression levels of xIAP, CART1 and CARF among various cell types (Figure 1a) . In contrast, c-IAP2 expression was observed only in MDA-MB-231, MDA-MB-436, MDA-MB-468 and HBL100 cells, all of which contain high levels of constitutive NF-kB DNA binding activity ( Figure 1a , Table 1 ). The c-IAP2 expression in these cells was further con®rmed by Northern blot analysis (data not shown). TRAF1 expression was observed in MDA-MB-231 and MDA-MB-436 cells. Cell type-speci®c variation in TRPM2 expression was observed but did not correlate with NF-kB DNA binding activity. The expression levels of the anti-apoptotic gene c-IAP1, Mn-SOD and survivin were measured by Northern blotting (Jones et al., 1997; Li et al., 1998; Wang et al., 1998) . While all cell lines expressed similar levels of c-IAP1 and survivin, Mn-SOD expression was higher in ERa-negative breast cancer cells with constitutive NFkB DNA binding activity (Figure 1b) . Increased expression of Mn-SOD in ERa-negative breast cancer cells was further con®rmed by Western blotting ( Figure  1c , Table 1 ). Dierential screening of Atlas TM human cancer cDNA array (Clontech, Palo Alto, CA, USA) using RNA form MDA-MB-231 cells and MDA-MB-231 cells modi®ed to overexpress IkBa super-repressor (IkBaSR) (Wang et al., 1996) identi®ed the antiapoptotic gene DAD-1 as an NF-kB inducible gene (data not shown) (Kelleher and Gilmore, 1997) . However, DAD-1 expression did not correlate with constitutive NF-kB DNA binding activity (Figure 1b) . Taken together, these results suggest that constitutive activation of NF-kB leads to increased mRNA and/or NF-kB DNA binding activity in these cells has been described (Newton et al., 1999) . Relative expression of c-IAP2 and Mn-SOD was calculated by densitometric scanning of autoradiograms ( Figure 1) protein levels of c-IAP2 and Mn-SOD in breast cancer cells.
IkBaSR inhibits c-IAP2, Mn-SOD, TRAF1 and DAD-1 expression in MDA-MB-231 cells
To further investigate whether c-IAP2 and Mn-SOD expression is dependent on NF-kB, we generated MDA-MB-231 cells overexpressing IkBaSR. Approximately 50% of colonies isolated using neomycin/G418 as a selection marker expressed IkBaSR (Figure 2a ). Most of these clones lost IkBaSR expression after continuous propagation in culture. Also, we did not obtain any clones completely devoid of constitutive NF-kB DNA binding activity. Three clones expressing IkBaSR (IkBaSR6, 8 and 10) and a clone containing retrovirus vector alone (LxSN11) were used for further studies.
Constitutive NF-kB DNA activity in these clones were measured by EMSA using the general transcription factor SP-1 as an internal control. IkBaSR6, IkBaSR8 and IkBaSR10 cells displayed 20, 10 and 40% lower NFkB DNA binding activity, respectively, than LxSN11 cells ( Figure 2b , lanes 1 ± 4). Similar results were obtained when EMSA was performed with nuclear extracts instead of whole cell extracts ( 
IkBaSR cells are more sensitive to paclitaxel than LxSN cells
Apoptosis by chemotherapeutic agents including paclitaxel involves activation of caspase 9 and caspase 3 (Thornberry and Lazebnik, 1998). Anti-apoptotic function of NF-kB is mostly due to Mn-SOD and c-IAP2 mediated inhibition of caspase 9 activation (Deveraux and Reed, 1999; Green and Reed, 1998) . Also c-IAP2 inhibits the activity of caspase 3 (Deveraux and Reed, 1999) . Recent studies have indicated that NF-kB alters cell cycle progression by modulating the expression of cell cycle regulatory genes (Guttridge et al., 1999; Hinz et al., 1999) . Based on these observations, we hypothesized that constitutively active NF-kB decreases the sensitivity of cancer cells to chemotherapeutic agents whose activity is cell cycledependent. After an initial survey of various chemotherapeutic drugs, paclitaxel was chosen for further study because of a consistent dierence in response of LxSN11 and IkBaSR cells to this drug. Paclitaxel is a microtubule-stabilizing agent whose action is concentration-dependent (Torres and Horwitz, 1998) . At 59 nM drug concentration, paclitaxel acts by retarding or inhibiting progression through mitosis, thus altering microtubule dynamics. At these concentrations, cells exit mitosis aberrantly and fractionate into hypodiploid populations during cell cycle analysis (Torres and Horwitz, 1998) . At 49 nM drug concentration, paclitaxel increases microtubule polymer mass, terminal G2/M arrest and cell death with a concomitant decrease in hypodiploid cells (Torres and Horwitz, 1998) . At 3 nM paclitaxel concentration, *30% of all cell types were hypodiploid (Figure 3a 4 cells grown overnight were incubated with paclitaxel for 18 h and apoptosis was measured by ELISA. The rate of spontaneous apoptosis in untreated LxSN11 cells was set as one unit and the relative dierence among cell types with or without paclitaxel treatment is shown Only diploid cells were considered while calculating the percentage of cells in dierent phases of the cell cycle. These results suggest that genes activated by NF-kB reduce the ability of paclitaxel to induce G2/M arrest.
It was demonstrated previously that rates of paclitaxel-induced apoptosis directly correlate with number of G2/M arrested cells rather than number of hypodiploid cells (Torres and Horwitz, 1998) . To determine whether increased G2/M arrest of IkBaSR cells is accompanied by increased apoptosis when compared to LxSN11 cells, we performed a`cell death' ELISA (Kumar et al., 1996) . To avoid loss of hypodiploid or other damaged cells during processing, the assay was performed with cell culture supernatants. After 18 h of paclitaxel treatment, there was only a marginal increase in apoptosis of LxSN11 cells, although a considerable number of cells were hypodiploid (Figure 3b) . In contrast, a substantial increase in apoptotic death of IkBaSR10 cells was observed after paclitaxel treatment. Similar results were obtained when cells were incubated for 48 h with paclitaxel ( Figure 3b ). Note that there is an increased rate of spontaneous apoptosis in IkBaSR10 cells compared to LxSN11 cells, which further suggests that NF-kB activity is required for survival of MDA-MB-231 cells. Taken together, these results indicate that breast cancer cells with constitutively active NF-kB require a higher concentration of paclitaxel for G2/M arrest and possibly for apoptosis.
To determine whether lack of NF-kB in normal cells leads to altered sensitivity to paclitaxel, we compared the cell cycle distributions of paclitaxel-treated ®broblasts derived from p65 7/7 with wild type littermate mouse embryos. Interestingly, paclitaxel had no eect on the cell cycle distribution of both wild type and p65
7/7
®broblasts suggesting that paclitaxel-induced G2/M arrest is restricted to cancer cells (Table 2) . Consistent with this possibility, paclitaxel caused G2/M arrest of several other breast cancer cell lines (data not shown).
Parthenolide, an active ingredient of feverfew, inhibits NF-kB DNA binding activity and increases the sensitivity of breast cancer cells to Paclitaxel
The above results suggest that inhibitors of NF-kB increase the sensitivity of cancer cells to paclitaxel without causing substantial damage to normal cells. Although gene therapy with IkBaSR has been suggested to overcome chemoresistance, we focused on synthetic and natural inhibitors of NF-kB activity. We ®rst determined whether curcumin, N-acetyl cysteine, pentoxyphylline, parthenolide, epigallocatechin gallate, Bay 11-7085 or MG-132 inhibit NF-kB DNA binding activity in breast cancer cells (Biswas et al., 1993; Hehner et al., 1998; Kumar et al., 1998; Lin et al., 1998; Pierce et al., 1997; Yang et al., 1998) . Among these compounds, only parthenolide, MG132 and Bay 11-7085 inhibited NF-kB DNA binding activity in MDA-MB-231 cells (Figure 4a , data not shown). Parthenolide inhibited constitutive NF-kB DNA binding activity in HBL100 cells (data not shown). We next examined the eect of parthenolide on NF-kB DNA binding activity in cells treated with paclitaxel. Although paclitaxel has been shown to induce NF-kB in other cell types (Das and White, 1997), untreated and paclitaxel-treated MDA-MB-231 cells displayed similar levels of NF-kB DNA binding activity (Figure 4b) . Nonetheless, parthenolide inhibited NF-kB DNA binding activity in paclitaxel-treated cells (Figure 4b ). Inhibition of NF-kB DNA binding activity by parthenolide correlated with reduced Mn-SOD expression in MDA-MB-231 cells (Figure 4c) .
We selected parthenolide for chemosensitization study because it is already in clinical use (Murphy et al., 1988) and was eective at very low concentrations. MDA-MB-231 and HBL100 cells were exposed to increasing concentrations of either paclitaxel or parthenolide and cell survival was measured after 18 h by an MTS assay. Half-maximal growth-inhibitory concentration (IC 50 ) was reached at 10 nM and 0.8 mM for paclitaxel and parthenolide, respectively, in HBL100 cells (data not shown). IC 50 s of 430 nM and 2 mM for paclitaxel and parthenolide, respectively, were obtained for MDA-MB-231 cells (data not shown). For unknown reasons, only 30% of MDA-MB-231 cells were killed when incubated with 30 nM or higher concentrations of paclitaxel. We next studied the eect of combination of 1 nM paclitaxel and increasing concentrations of parthenolide. The IC 50 of parthenolide decreased to 50.1 mM and *0.8 mM for HBL100 and MDA-MB-231 cells, respectively ( Figure 4d ). As per the Isobole method, these results translate into a 43.5-fold synergism with drug combination for HBL100 cells. Although we could not accurately calculate fold synergism for MDA-MB-231 cells, the eect of combination therapy was more than additive.
To investigate whether the simultaneous exposure to paclitaxel and parthenolide leads to G2/M arrest and apoptosis, we performed cell cycle distribution analysis and`cell death ELISA' of untreated and treated HBL100 cells. Parthenolide had no eect on the cell cycle distribution of HBL100 cells (data not shown). Cells treated with either paclitaxel alone or in combination with parthenolide were arrested at G2/ M, although a synergistic eect of drug combination on G2/M arrest was only observed in some experiments (data not shown). Paclitaxel alone induced apoptosis to a certain degree whereas parthenolide Paclitaxel G0/G1 S G2/M G0/G1 S G2/M 69+2 1 2 +5 1 9 +3 4 7 +1 4 9 +1 4 +2 1 nM 68+4 2 0 +4 1 7 +8 4 7 +2 5 3 +1 ± 3 nM 70+3 1 6 +1 1 4 +5 3 9 +6 6 1 +7 1 5 nM 71+3 1 6 +4 1 7 +6 4 7 +2 4 6 +6 1 4 10 nM 73+2 1 5 +2 1 6 +6 4 7 +2 4 8 +6 6 +4
Cells were treated with indicated concentration of paclitaxel and cell cycle distribution was measured after 18 h of treatment
Role of NF-kB in breast cancer NM Patel et al was ineective (Figure 5a) . A synergistic increase in apoptosis was observed when cells were exposed to a combination of parthenolide and paclitaxel (Figure 5a ). To further con®rm that combination therapy induces apoptosis, we measured the cleavage of PARP from 116 to 85 kDa protein by caspases (Panvichian et al., 1998) . No PARP cleavage product was observed when HBL100 cells were incubated with either paclitaxel (1 and 5 nM) or parthenolide (0.1 and 0.5 mM) alone (Figure 5b ). In contrast, PARP cleavage product was detected when cells were treated with a combination of 5 nM paclitaxel and 0.5 mM parthenolide. Note that PARP cleavage was not detected in cells treated with low concentrations of paclitaxel and parthenolide, although cell death at these concentrations was measurable in MTS assays. This discrepancy is most likely due to dierences in the sensitivity of the two assays. Nevertheless, these results suggest that inhibition of NF-kB activity can increase the rate of apoptotic cell death by paclitaxel.
Discussion
In this study, we show that constitutive NF-kB DNA binding activity in breast cancer cells correlates with increased expression of the anti-apoptotic genes c-IAP2 and Mn-SOD. We have also demonstrated that constitutive NF-kB DNA binding correlates with increased expression of the pro-metastatic genes urokinase plasminogen activator, IL-6 and IL-8 (Newton et al., 1999) . These observations have enormous signi®cance because constitutive NF-kB DNA binding has been observed in 65% of primary breast cancers (Sovak et al., 1997) .
c-IAP2 and Mn-SOD are the major NF-kB inducible anti-apoptotic genes in breast cancer cells
Our studies identi®ed c-IAP2 as a major NF-kB inducible gene in breast cancer cells. Preliminary evidence obtained using reverse transcriptase-polymerase chain reaction analysis of tumor RNA indicates that c-IAP2 is overexpressed in primary breast cancers (data not shown). c-IAP2 is a more potent inhibitor of caspase 3 and caspase 7 activity than c-IAP1, and can suppress apoptosis induced by a variety of stimuli including TNF, Fas, menadione, staurosporine, etoposide, paclitaxel and growth factor withdrawal (Deveraux and Reed, 1999). Previously, it was reported that reduced expression of the pro-apoptotic gene Bax is responsible for chemoresistance in breast cancer (Bargou et al., 1996) . Bax activates caspase-dependent and caspase-independent apoptotic pathways (Xiang et al., 1996) . Our results raise the possibility that constitutively active NF-kB through c-IAP2 may confer chemoresistance even in tumors that express Bax because c-IAP2 can block the caspase-dependent apoptotic pathway (Deveraux and Reed, 1999) . Paclitaxel is a commonly used chemotherapeutic agent in both the adjuvant and metastatic settings. c-IAP2 expression might represent a potential predictor of response to this important agent. Although constitutive NF-kB activation is one mechanism of c-IAP2 overexpression, we cannot rule out ampli®cation of the c-IAP2 gene since it is located on chromosome 11q22-23, a frequently altered chromosomal segment in breast and renal cell carcinomas (Deveraux and Reed, 1999; Jiang et al., 1998) .
Mn-SOD appears to have dual role in cancer. Mn-SOD can reduce oxidative stress, protect against DNA damage and prevent initiation of cancerous mutation (Oberley and Oberley, 1997). Consistent with this possibility, the incidence of breast cancer is higher in premenopausal women who have inherited the polymorphic variant of Mn-SOD with reduced biological activity (Ambrosone et al., 1999) . However, Mn-SOD may also protect cancer cells from chemotherapyinduced oxidative stress and apoptosis (Manna et al., 1998) . Indeed, overexpression of Mn-SOD alone is sucient to confer resistance to okadaic acid, H 2 O 2 , and paclitaxel but not vincristine-, vinblastine-and daunomycin-induced apoptosis of breast cancer cells (Manna et al., 1998) . These observations raise the possibility that NF-kB may also have a dual role in mammary epithelial cells. By upregulating Mn-SOD and other anti-oxidant genes, NF-kB may protect normal mammary epithelial cells from oxidative stress and DNA damage. In cancer cells, however, these antioxidant gene products may protect against chemotherapy-induced oxidative stress and apoptosis. Further studies are required to de®ne the speci®c role of Mn-SOD in the growth of normal and malignant mammary epithelial cells.
IkBaSR reduced the expression of DAD-1 and TRAF1 in MDA-MB-231 cells suggesting the requirement of NF-kB for the expression of these genes. However, DAD-1 is expressed in cell types lacking constitutively active NF-kB suggesting that NF-kB is not absolutely required for DAD-1 expression. In contrast to DAD-1, TRAF1 expression was observed in only a few cell types that contained constitutively active NF-kB. Cell type-speci®c transcription factors or chromatin organization, in addition to NF-kB, may have an in¯uence on TRAF1 expression.
It was reported recently that caspases activated during apoptosis cleave NF-kB and attenuate antiapoptotic response (Levkau et al., 1998) . Therefore, although several chemotherapeutic agents including paclitaxel induce NF-kB (Das and White, 1997) , it is less likely that activated NF-kB can mount an antiapoptotic response. However, NF-kB can protect against chemotherapeutic agents if it is constitutively active and, as a consequence, cells constitutively express Mn-SOD and c-IAP2. Therefore, IkBaSR or NF-kB inhibitors may be useful in overcoming chemotherapeutic resistance of only those cells that contain constitutively active NF-kB. Consistent with 5 cells were treated with the indicated drugs. Cells were lysed 24 h after paclitaxel addition, and the lysate was examined for uncleaved (p116) and cleaved PARP (p85) by Western blotting this possibility, IkBaSR overexpression in HPB, HCT116, MCF-7, and OVCAR-3 cells, all of which lack constitutively active NF-kB, did not increase the sensitivity to paclitaxel (Bentires-Aji et al., 1999) .
Paclitaxel-induced G2/M arrest and apoptosis is regulated by NF-kB
We observed that IkBaSR overexpressing MDA-MB-231 cells require lower concentrations of paclitaxel to arrest at the G2/M phase when compared to LxSN11 cells. We ®rst suspected that NF-kB upregulates survivin, which directly associates with microtubules and prevents paclitaxel-induced G2/M arrest (Li et al., 1998) . However, both LxSN11 and IkBaSR cells expressed similar levels of survivin (Figure 2d ). Paclitaxel-induced G2/M arrest and apoptosis requires the activity of p34 cdc2 kinase (Shen et al., 1998) . We did not observe signi®cant dierences in p34 cdc2 activity among LxSN11 and IkBaSR cells (data not shown). It is unlikely that LxSN11 and IkBaSR cells dier with respect to paclitaxel uptake and eux, because calcein-AM uptake and eux (which indirectly measure mdr-1 and mrp-1 activity, respectively) was similar in both cell types (data not shown) (Legrand et al., 1998) . Moreover, MDA-MB-231 cells do not express a classical multi-drug-resistance phenotype (Ferlini et al., 1997) . It was demonstrated previously that paclitaxel-induced G2/M arrest and/or apoptosis is accompanied by phosphorylation of Bcl-2 (Blagosklonny et al., 1996; Ling et al., 1998) . However, we did not observe phosphorylation of Bcl-2 in MDA-MB-231 cells under any treatment conditions (data not shown). The dierences in paclitaxel-induced G2/M arrest, therefore, could be related to other paclitaxel induced changes in cell signaling, including activation of c-Raf-1 and c-JUN NH-2 terminal kinase (Amato et al., 1998; Blagosklonny et al., 1995) . In addition, NF-kB may regulate the expression of genes involved in microtubule dynamics (Cassimeris, 1999) and it is the impaired expression of these genes in cells with constitutive NF-kB responsible for reduced sensitivity to paclitaxel.
A survey of a number of known inhibitors of NF-kB revealed that parthenolide can function similar to IkBaSR by increasing the sensitivity of breast cancer cells to paclitaxel. However, the degree of synergism appears to be dependent on the cell type, as HBL100 cells were more sensitive to the combined treatment than MDA-MB-231 cells. The cell type-speci®c eect may be related to dierences in the stability of parthenolide within cells or the number of cell survival pathways that are active in a particular cell type. We propose that the NF-kB-mediated survival pathway is the major cell survival pathway in HBL100 cells, whereas NF-kB-independent survival pathways provide partial protection to MDA-MB-231 cells. This possibility is supported by other in vitro observations that MDA-MB-231 cells represent a more`advanced cancer cell type' (with respect to growth in nude mice) than HBL100 cells (Price et al., 1990; Sommers et al., 1994) . In cancer types that are dependent on NF-kB, a combination of parthenolide and chemotherapeutic drugs may be bene®cial. Our preliminary results with p65 7/7 cells (Table 2) suggest that such an approach is less likely to be toxic to normal cells. Apart from parthenolide, there are other medicinal plants including the genera Berberis, Coptis and Gravel root with antiin¯ammatory properties (Fukuda et al., 1999; Habtemariam, 1998 ). These plants may be an ideal source of NF-kB inhibitors and can be explored as therapeutic agents for breast cancer.
Materials and methods
Breast cancer cells lines
All breast cancer cell lines were purchased from the American Type Tissue Culture Collection (Rockville, MD, USA) and grown as described previously (Bhat-Nakshatri et al., 1998) . Wild type and p65 7/7 ®broblast cells were gift from D Baltimore and A Homann (Beg and Baltimore, 1996) .
Generation of MDA-MB-231 cells overexpressing IkBa super-repressor
IkBa super-repressor (IkBaSR) plasmid containing S32A and S36A mutation of IkBa was generated by PCR mediated sitedirected mutagenesis and cloned into the EcoRI site of the modi®ed retrovirus vector LxSN (Miller and Rosman, 1989; Wang et al., 1996) . Retrovirus and stable IkBaSR expressing MDA-MB-231 clones were prepared as described previously (Newton et al., 1999) .
Electrophoretic mobility shift assays (EMSAs)
Whole cell extracts were prepared and subjected to EMSA with NF-kB and SP-1 probes (Promega, Madison, WI, USA) (Newton et al., 1999) . Nuclear extracts were prepared as described previously (Dignam et al., 1983) . Antibodies for supershift assays were purchased from Santa Cruz Biotechnology (CA, USA) or Upstate Biotechnology (NY, USA).
Western blotting
Total cell lysates were prepared in radioimmunoassay buer and subjected to Western blotting as described previously (Newton et al., 1999) . IkBa and Mn-SOD antibodies were purchased from Santa Cruz Biotechnology and Upstate Biotechnology, respectively.
Northern blotting and RNase protection
Total RNA was subjected to Northern blotting as described previously (Newton et al., 1999) . Twenty mgs of RNA were subjected to RNase protection using the hAPO-5 probe (PharMingen, San Diego, CA, USA) as described by the manufacturers.
Drug treatment, cell death assays, apoptosis assay and PARP cleavage
For cell death assays, 2610 3 cells grown overnight on a 96-well plate were treated with paclitaxel and/or parthenolide (dissolved in ethanol). In combination treatment, parthenolide was added 4 h before paclitaxel treatment. Cell death was measured 18 h after paclitaxel treatment using the MTS assay (Promega, Madison, WI, USA). Apoptosis was measured by a histone-ELISA (Roche Diagnostics, Indianapolis, IN, USA). 5610 4 cells grown overnight on six-well plates were treated with paclitaxel for indicated times. Histone-DNA complexes in the supernatant were detected by ELISA. For the PARP cleavage assay, 5610 5 cells were exposed to the indicated drugs for 24 h. Both adherent and non-adherent cells were collected, lysed in urea-sodium dodecyl sulfate buer and subjected to Western blotting with PARP antibody (Enzyme System Products, Livermore, CA, USA) (Panvichian et al., 1998) .
Flow cytometry
5610
5 cells grown overnight were treated with the indicated concentrations of paclitaxel for 18 h. Cells were collected by trypsinization, washed in phosphate-buered saline and resuspended in 125 ml of 2 mg/ml RNase and 300 ml of propidium iodide containing buer (50 mg/ml propidium iodide, 1 mg/ml sodium citrate, 0.03% NP40). The amount of propidium iodide incorporated was determined by FACScan analysis and the cell cycle distribution was determined using ModFit computer Software. Cell cycle distribution analysis was performed in a single blinded manner. Only diploid cells were considered while calculating the percentage of cells at each phase of cell cycle.
Statistical analysis
In synergy experiments, dose-response curves for single agents were generated ®rst. The eect of combined treatment was analysed by the Isobole method (Berenbaum, 1981) .
